Cancer Immunotherapy

Immune Suppression and Tumor Growth

Edited by

  • George Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.
  • Elizabeth Jaffee, Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.
View full description


Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients


Book information

  • Published: June 2007
  • ISBN: 978-0-12-372551-6


This relatively compact book is a summary of contemporary thinking about cancer immunotherapy, with a focus on the relationship between tumors and the immune response of the host. The book is edited by authorities on tumor biology and cancer immunotherapy and reflects the nascent synthesis of these disciplines. The chapters are written by highly respected investigators, and the topics span much of the breadth and depth of this evolving field. The book seems designed to provide an overview for those who wish to immerse themselves in this field and who have a working knowledge of immunotherapy but rudimentary familiarity with cancer immunobiology and therapy. - The New England Journal of Medicine, April 2008

Table of Contents

Part I: Principles of Cancer ImmunobiologyIntroductionCancer Immunoediting: From Immune Surveillance to Immune EscapeImmunosurveillance: Innate and Adaptive Anti-Tumor ImmunityCytokine Regulation of Immune Tolerance to TumorsImmunological Sculpting: Natural Killer Cell Receptors and LigandsImmune Escape: Immunosuppressive NetworksPart II: Cancer TherapeuticsCytotoxic Chemotherapy in Clinical Treatment of CancerTargeted Therapeutics in Cancer TreatmentConcepts in Pharmacology and ToxicologyCancer Immunotherapy: Challenges and OpportunitiesCancer VaccinesPart III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune SuppressionImmunotherapy and Cancer Therapeutics: Why Partner?Immune Stimulatory Features of Classical ChemotherapyDendritic Cells and Co-Inhibitory MoleculesRegulatory T Cells in Tumor Immunity: Role of Toll-like Receptors Tumor-associated Macrophages in Cancer Growth and ProgressionTumor-associated Myeloid-derived Suppressor CellsProgrammed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune EscapeIDO in Immune Escape: Regulation and Therapeutic InhibitionArginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune ModulationSummary: Future Questions